文献速递造血干细胞移植与细胞治疗

IL-6受体抑制促进细胞免疫治疗后细胞溶解性CD4+ T细胞扩增

IL-6 receptor inhibition promotes expansion of cytolytic CD4+ T cells after cellular immunotherapy.
PubMed 文献 · Blood · 2026-01-01

该研究在异基因造血干细胞移植(HSCT)临床试验中,对接受IL-6受体(IL-6R)抑制(托珠单抗TCZ或安慰剂)联合钙调神经磷酸酶抑制剂和短程甲氨蝶呤的患者样本进行单细胞RNA测序,分析循环CD14+单核细胞和CD4+ T细胞。结果显示IL-6R抑制促进I型干扰素相关转录程序,并显著增强细胞溶解性CD4+ T细胞分化;实验模型中供者T细胞IL-6信号缺失可扩增Eomes+ CD4+调节性T细胞亚群、减弱Th1和Th17分化,并改善抗肿瘤效应。

要点

  • IL-6R抑制在HSCT患者中促进CD4+ T细胞和CD14+单核细胞的I型干扰素转录程序。
  • TCZ显著增强细胞溶解性CD4+ T细胞分化。
  • 供者T细胞IL-6信号缺失扩增Eomes+ CD4+调节性T细胞并改善抗肿瘤效应。

核心结论

  • IL-6R抑制在细胞治疗期间 imprint I型干扰素程序并促进细胞溶解性CD4+ T细胞分化,包括与良好免疫治疗结局相关的Eomes+亚群。

研究设计与样本

  • 在IL-6R抑制(TCZ或安慰剂)联合钙调神经磷酸酶抑制剂和短程甲氨蝶呤的临床试验中,对患者循环CD14+单核细胞和CD4+ T细胞进行单细胞RNA测序。
  • 研究纳入未发生急性GVHD的患者,并包含一个在aGVHD发生前分析的安慰剂组。
  • 利用实验性HSCT和嵌合抗原受体T细胞系统进行供者T细胞IL-6信号遗传删除研究。

主要发现

  • IL-6R抑制在CD4+ T细胞和CD14+单核细胞中促进I型干扰素相关转录程序。
  • TCZ深度增强细胞溶解性CD4+ T细胞分化。
  • 实验系统中供者T细胞IL-6信号遗传删除增强Eomes+ CD4+调节性T细胞亚群扩增并减弱Th1和Th17分化。
  • IL-6信号缺失时抗肿瘤效应改善。

临床怎么用

  • 提示IL-6R抑制可能通过促进细胞溶解性CD4+ T细胞分化影响HSCT后免疫重建与抗肿瘤效应,需进一步临床验证。

局限性

  • 研究基于特定临床试验样本与实验模型,人体免疫效应机制仍需更大规模研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) remains a major barrier to the success of allogeneic hematopoietic stem cell transplantation (HSCT). In preclinical models, the dysregulation of interleukin-6 (IL-6) in the peritransplant period promotes GVHD via STAT3-dependent T-cell differentiation and monocyte activation, but the nature of immunological effects invoked in patients remains unclear. To advance our understanding of IL-6 signaling in humans during HSCT, we performed single-cell RNA sequencing on circulating CD14+ monocytes and CD4+ T cells from patient samples within a clinical trial of IL-6 receptor (IL-6R) inhibition (tocilizumab [TCZ] or placebo) on a backbone of calcineurin inhibition and short-course methotrexate. We studied patients who did not develop acute GVHD (aGVHD) and included a placebo-treated group analyzed before the development of aGVHD. IL-6R inhibition promoted type I interferon-associated transcriptional programs in both CD4+ T cells and CD14+ monocytes. Surprisingly, IL-6R inhibition with TCZ profoundly enhanced cytolytic CD4+ T-cell differentiation. In experimental HSCT and chimeric antigen receptor T-cell systems, the genetic deletion of IL-6 signaling in donor T cells enhanced the expansion of cytolytic eomesodermin-positive (Eomes+) CD4+ regulatory T cell subsets and attenuated T helper 1 (Th1) and Th17 differentiation. Consistent with the promotion of this cytolytic CD4+ phenotype, antitumor effects were improved in the absence of IL-6 signaling. In summary, these data demonstrate that IL-6R inhibition during cell therapy imprints type I interferon programs and cytolytic CD4+ T-cell differentiation, including the Eomes+ fraction associated with favorable immunotherapy outcomes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Williams CG, Zhang P, Adams RC, et al. IL-6 receptor inhibition promotes expansion of cytolytic CD4+ T cells after cellular immunotherapy. Blood. 2026. PMID: 42485668. doi:10.1182/blood.2025032420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。